Welcome to Oncogene

Publishing the latest research on the cellular and molecular biology of cancer including resistance to cancer therapies, and the development of better approaches to improving survival. 


  • A sincere thank you to all of the reviewers listed here, who took the time to review for Oncogene in 2020. The journal could not exist without the knowledge and critical evaluation provided by our reviewers - content is often vastly improved by the suggestions and recommendations they provide.

  • Twitter logo

    Join the Oncogene Twitter Community @oncogenejournal. Follow us to keep up-to-date with the latest research and news from Oncogene. Share your views, retweet and give us feedback.

  • Join Nature Cancer's Chief Editor, Alexia-Ileana Zaromytidou, alongside Prof Adrian Harris, Drs Jan-Paul Medema, Haidong Dong, and Yi-Long Wu, for the first in a new series of Springer Nature webinars that will bring together international experts to discuss ongoing developments in cancer research.

    Thursday 24 June 2021, 8-9.30 am (EDT), 2-3.30 pm (CET), 8-9.30 pm (CST)

Oncogene is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.


Focus on…Breast Cancer Research

Focus on…Breast Cancer Research

Breast cancer is the most common invasive cancer in women and the second leading cause of cancer death in women after lung cancer. Great strides have been made in treatment options and targeted therapies but research continues to further improve survival rate.